NCT01827787View on ClinicalTrials.gov

Eribulin in HER2 Negative Metastatic BrCa

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Eribulin

Trial Locations (7)

04402

Eastern Maine Medical Center, Bangor

02130

Dana-Farber Cancer Institute at Faulkner Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01757

DF/BWCC at Milford Regional Cancer Center, Milford

02190

South Shore Hospital, Weymouth

03053

Dana-Farber/New Hampshire Oncology-Hematology, Londonderry

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01827787 - Eribulin in HER2 Negative Metastatic BrCa | Biotech Hunter | Biotech Hunter